MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Endries International, Brillion, WI, a distributor of fasteners and related production components, has announced that MSD Partners, L.P., along with Endries management, has acquired Endries from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback